glp-1 drugs for addiction IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target GLP-1 Drugs As Candidates for
Description
[DOI] [PubMed] [Google Scholar] 48.Vonlaufen A, Wilson JS, Apte MV
Figure 2 presents a schematic flowchart illustrating the sequential steps involved in the mechanism of GLP-1 action
Data suggest Tirzepatide may help retain more lean mass during weight loss compared to Semaglutide, making it attractive for those aiming to cut fat without sacrificing muscle
2025 Jan 1;82(1):94-98
Another midstage trial found that diabetic patients who took a 200-milligram version of danuglipron twice a day lost nearly 12 pounds, or 5.8% of their weight, on average after 12 weeks
10.2337/db11-0227 38 FarrO
